Supernus Pharmaceuticals (SUPN) Upgraded by Zacks Investment Research to “Buy”

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The brokerage presently has a $44.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 16.59% from the stock’s current price.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Get Supernus Pharmaceuticals alerts:

Several other research firms have also recently commented on SUPN. Cowen set a $55.00 price objective on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Supernus Pharmaceuticals in a research report on Friday, November 23rd. ValuEngine cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 6th. B. Riley set a $65.00 price objective on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 4th. Finally, Piper Jaffray Companies set a $44.00 price objective on Supernus Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, January 16th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $55.75.

Supernus Pharmaceuticals stock opened at $37.74 on Wednesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.90 and a current ratio of 3.06. Supernus Pharmaceuticals has a one year low of $30.05 and a one year high of $61.25. The firm has a market cap of $2.01 billion, a P/E ratio of 18.41 and a beta of 1.62.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.29 by $0.19. Supernus Pharmaceuticals had a return on equity of 27.45% and a net margin of 27.14%. The company had revenue of $113.50 million for the quarter, compared to analysts’ expectations of $105.36 million. During the same period last year, the firm posted $0.26 earnings per share. Supernus Pharmaceuticals’s revenue was up 31.4% compared to the same quarter last year. As a group, equities analysts anticipate that Supernus Pharmaceuticals will post 2.37 EPS for the current fiscal year.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $41.53, for a total value of $830,600.00. Following the transaction, the chief financial officer now directly owns 67,896 shares of the company’s stock, valued at $2,819,720.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.20% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Menta Capital LLC boosted its position in Supernus Pharmaceuticals by 3.5% in the fourth quarter. Menta Capital LLC now owns 7,824 shares of the specialty pharmaceutical company’s stock worth $260,000 after purchasing an additional 265 shares during the last quarter. Victory Capital Management Inc. boosted its position in Supernus Pharmaceuticals by 4.1% in the fourth quarter. Victory Capital Management Inc. now owns 7,536 shares of the specialty pharmaceutical company’s stock worth $250,000 after purchasing an additional 296 shares during the last quarter. Advisor Group Inc. boosted its position in Supernus Pharmaceuticals by 17.2% in the fourth quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 306 shares during the last quarter. Mizuho Securities USA LLC boosted its position in Supernus Pharmaceuticals by 3.4% in the fourth quarter. Mizuho Securities USA LLC now owns 12,000 shares of the specialty pharmaceutical company’s stock worth $399,000 after purchasing an additional 400 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. boosted its position in Supernus Pharmaceuticals by 3.4% in the fourth quarter. Piedmont Investment Advisors Inc. now owns 12,377 shares of the specialty pharmaceutical company’s stock worth $411,000 after purchasing an additional 409 shares during the last quarter. 97.89% of the stock is currently owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Read More: Mutual Funds

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Leave a Reply

Your email address will not be published. Required fields are marked *